Lawrence A. Leiter

MDCM, FRCPC, FACP, FACE, FAHA

Investigator

Biography

Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 750 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas. In 2018, 2019, and 2020 he was a Clarivate Analytics Top 1% Highly Cited Researcher

Dr. Leiter is a past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Distinguished Service Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.  In 2019 was elected as a Fellow of the Canadian Academy of Health Sciences

Recent Publications

  1. Mancini, GBJ, O'Meara, E, Zieroth, S, Bernier, M, Cheng, AYY, Cherney, DZI et al.. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Can J Cardiol. 2022;38 (8):1153-1167. doi: 10.1016/j.cjca.2022.04.029. PubMed PMID:35961754 .
  2. Lee, JJ, Khan, TA, McGlynn, N, Malik, VS, Hill, JO, Leiter, LA et al.. Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes Care. 2022;45 (8):1917-1930. doi: 10.2337/dc21-2130. PubMed PMID:35901272 .
  3. Lee, D, Chiavaroli, L, Ayoub-Charette, S, Khan, TA, Zurbau, A, Au-Yeung, F et al.. Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials. Nutrients. 2022;14 (14):. doi: 10.3390/nu14142846. PubMed PMID:35889803 PubMed Central PMC9325155.
  4. Miller, M, Tokgozoglu, L, Parhofer, KG, Handelsman, Y, Leiter, LA, Landmesser, U et al.. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Rev Cardiovasc Ther. 2022; :1-17. doi: 10.1080/14779072.2022.2103541. PubMed PMID:35876118 .
  5. Oyama, K, Raz, I, Cahn, A, Goodrich, EL, Bhatt, DL, Leiter, LA et al.. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2022; :. doi: 10.1001/jamacardio.2022.2006. PubMed PMID:35857296 PubMed Central PMC9301591.
  6. Schechter, M, Melzer Cohen, C, Yanuv, I, Rozenberg, A, Chodick, G, Bodegård, J et al.. Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults. Cardiovasc Diabetol. 2022;21 (1):104. doi: 10.1186/s12933-022-01521-9. PubMed PMID:35689214 PubMed Central PMC9188046.
  7. Hramiak, I, Gerstein, HC, Leiter, LA, Yale, JF, Bajaj, HS, Stewart, J et al.. Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial. Diabetes Obes Metab. 2022; :. doi: 10.1111/dom.14787. PubMed PMID:35670659 .
  8. Strain, WD, Frenkel, O, James, MA, Leiter, LA, Rasmussen, S, Rothwell, PM et al.. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022; :101161STROKEAHA121037775. doi: 10.1161/STROKEAHA.121.037775. PubMed PMID:35582947 .
  9. Furtado, RHM, Raz, I, Goodrich, EL, Murphy, SA, Bhatt, DL, Leiter, LA et al.. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation. 2022;145 (21):1581-1591. doi: 10.1161/CIRCULATIONAHA.121.058103. PubMed PMID:35510542 .
  10. Steg, PG, Bhatt, DL, James, SK, Darlington, O, Hoskin, L, Simon, T et al.. Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. Eur Heart J Cardiovasc Pharmacother. 2022; :. doi: 10.1093/ehjcvp/pvac032. PubMed PMID:35488865 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto